Kevin Shannon

Kevin Shannon

Auto-generated profile, based on publicly available information

Kevin Shannon

Department of Pediatrics, University of California, San Francisco, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Nature
Verified
Journal Article
Open access
PDF file
JCJulia Carnevale
Julia Carnevale
ESEric Shifrut
Eric Shifrut
NKNupura Kale
Nupura Kale
WNWilliam A. Nyberg
William A. Nyberg
FBFranziska Blaeschke
Franziska Blaeschke
AMAlex Marson
Alex Marson
The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints1,2. Targeted gene editing has the potential to overcome these limitations and enhance T cell therapeutic function3–10. Here we performed multiple genome-wide CRISPR knock-out screens under different immunosuppressive conditions to identify genes that can be targeted to prevent T cell dysfunction. These screens converged on RASA2, a RAS GTPase-activating protein (RasGAP) that we identify as a signalling checkpoint in human T cells, which is downregulated upon acute T cell receptor stimulation and can increase gradually with chronic antigen exposure. RASA2 ablation enhanced MAPK signalling and chimeric antigen receptor (CAR) T cell cytolytic activity in response to target antigen. Repeated tumour antigen stimulations in vitro revealed that RASA2-deficient T cells show increased activation, cytokine production and metabolic activity compared with control cells, and show a marked advantage in persistent cancer cell killing. RASA2-knockout CAR T cells had a competitive fitness advantage over control cells in the bone marrow in a mouse model of leukaemia. Ablation of RASA2 in multiple preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenografted with either liquid or solid tumours. Together, our findings highlight RASA2 as a promising target to enhance both persistence and effector function in T cell therapies for cancer treatment.

25 October 2012 in Blood
Verified
Journal Article
Open access
PDF file
AWAshley F. Ward
Ashley F. Ward
BBBenjamin S. Braun
Benjamin S. Braun
KSKevin M. Shannon
Kevin M. Shannon
Ras proteins are critical nodes in cellular signaling that integrate inputs from activated cell surface receptors and other stimuli to modulate cell fate through a complex network of effector pathways. Oncogenic RAS mutations are found in ∼ 25% of human cancers and are highly prevalent in hematopoietic malignancies. Because of their structural and biochemical properties, oncogenic Ras proteins are exceedingly difficult targets for rational drug discovery, and no mechanism-based therapies exist for cancers with RAS mutations. This article reviews the properties of normal and oncogenic Ras proteins, the prevalence and likely pathogenic role of NRAS, KRAS, and NF1 mutations in hematopoietic malignancies, relevant animal models of these cancers, and implications for drug discovery. Because hematologic malignancies are experimentally tractable, they are especially valuable platforms for addressing the fundamental question of how to reverse the adverse biochemical output of oncogenic Ras in cancer.

1 February 2017 in Cell
Verified
Journal Article
Closed access
MBMichael R. Burgess
Michael R. Burgess
EHEugene Hwang
Eugene Hwang
RMRana Mroue
Rana Mroue
CBCraig M. Bielski
Craig M. Bielski
AWAnica M. Wandler
Anica M. Wandler
KSKevin Shannon
Kevin Shannon

2 September 2009 in Nature
Verified
Journal Article
Open access
PDF file
JLJennifer O. Lauchle
Jennifer O. Lauchle
DKDoris Kim
Doris Kim
DLDoan T. Le
Doan T. Le
KAKeiko Akagi
Keiko Akagi
MCMichael Crone
Michael Crone
KSKevin Shannon
Kevin Shannon
In a mouse model for myeloproliferative disorder (MPD) driven by loss of NF-1 (which activates the Ras–MEK–MAPK pathway), additional mutations were created by insertional mutagenesis that led to progression of the disease to acute myeloid leukaemias (AMLs). Interestingly, MEK inhibitors are not effective in mice with MPD, but lead to tumour regression in AMLs. However, these mice eventually develop resistance to MEK inhibitors. This was linked to insertional mutagenesis at genes encoding RasGRP1 and p38 in subclones of the AMLs that are present prior to and selected for during treatment with MEK inhibitors. In human cancers with deregulated Ras signalling, including tumours that have inactivated the Nf1 tumour suppressor, the cascade comprising Raf, mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) is a therapeutic target. Here, in mice, the effects of inhibitors of MEK in a model of myeloproliferative disorder initiated by inactivating Nf1 and in a model of acute myeloid leukaemia are compared. The cascade comprising Raf, mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) is a therapeutic target in human cancers with deregulated Ras signalling, which includes tumours that have inactivated the Nf1 tumour suppressor1,2. Nf1 encodes neurofibromin, a GTPase-activating protein that terminates Ras signalling by stimulating hydrolysis of Ras–GTP. We compared the effects of inhibitors of MEK in a myeloproliferative disorder (MPD) initiated by inactivating Nf1 in mouse bone marrow and in acute myeloid leukaemias (AMLs) in which cooperating mutations were induced by retroviral insertional mutagenesis. Here we show that MEK inhibitors are ineffective in MPD, but induce objective regression of many Nf1-deficient AMLs. Drug resistance developed because of outgrowth of AML clones that were present before treatment. We cloned clone-specific retroviral integrations to identify candidate resistance genes including Rasgrp1, Rasgrp4 and Mapk14, which encodes p38α. Functional analysis implicated increased RasGRP1 levels and reduced p38 kinase activity in resistance to MEK inhibitors. This approach represents a robust strategy for identifying genes and pathways that modulate how primary cancer cells respond to targeted therapeutics and for probing mechanisms of de novo and acquired resistance.

29 April 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JRJarrett R. Remsberg
Jarrett R. Remsberg
RSRadu M. Suciu
Radu M. Suciu
NZNoemi A. Zambetti
Noemi A. Zambetti
THThomas W. Hanigan
Thomas W. Hanigan
AFAri J. Firestone
Ari J. Firestone
BCBenjamin F. Cravatt
Benjamin F. Cravatt

10 February 2011 in Blood
Verified
Journal Article
Open access
PDF file
QLQing Li
Qing Li
KHKevin M. Haigis
Kevin M. Haigis
AMAndrew McDaniel
Andrew McDaniel
EHEmily Harding-Theobald
Emily Harding-Theobald
SKScott C. Kogan
Scott C. Kogan
KSKevin Shannon
Kevin Shannon
NRAS is frequently mutated in hematologic malignancies. We generated Mx1-Cre, Lox-STOP-Lox (LSL)-NrasG12D mice to comprehensively analyze the phenotypic, cellular, and biochemical consequences of endogenous oncogenic Nras expression in hematopoietic cells. Here we show that Mx1-Cre, LSL-NrasG12D mice develop an indolent myeloproliferative disorder but ultimately die of a diverse spectrum of hematologic cancers. Expressing mutant Nras in hematopoietic tissues alters the distribution of hematopoietic stem and progenitor cell populations, and Nras mutant progenitors show distinct responses to cytokine growth factors. Injecting Mx1-Cre, LSL-NrasG12D mice with the MOL4070LTR retrovirus causes acute myeloid leukemia that faithfully recapitulates many aspects of human NRAS-associated leukemias, including cooperation with deregulated Evi1 expression. The disease phenotype in Mx1-Cre, LSL-NrasG12D mice is attenuated compared with Mx1-Cre, LSL-KrasG12D mice, which die of aggressive myeloproliferative disorder by 4 months of age. We found that endogenous KrasG12D expression results in markedly elevated Ras protein expression and Ras-GTP levels in Mac1+ cells, whereas Mx1-Cre, LSL-NrasG12D mice show much lower Ras protein and Ras-GTP levels. Together, these studies establish a robust and tractable system for interrogating the differential properties of oncogenic Ras proteins in primary cells, for identifying candidate cooperating genes, and for testing novel therapeutic strategies.